Related by context. All words. (Click for frequent words.) 80 Common Terminology Criteria 67 abacavir Ziagen 65 histological subtype 64 FluCAM arm 64 nonmetastatic 63 papillary renal cell carcinoma 63 Digital Mammographic Imaging 63 relapsed MM 63 #-# Full Text 63 histologic subtype 63 infliximab etanercept 63 PREZISTA r arm 63 recurrent metastatic 63 Prolongs Survival 63 CIN2 + 63 Cancer Incidence Mortality 62 Stroke Scale NIHSS 62 Intervention Trial 62 NSABP B 62 Pediatric Oncology Branch 62 ß blockers 62 FDG PET imaging 62 STRIDE PD 62 cough dyspnea 62 haematologic 62 neutropaenia 62 Clinical Practice Guideline 62 chills fever headache 62 recurrent glioblastoma multiforme 62 Platinol ® 61 liposomal amphotericin B 61 intraepithelial neoplasia 61 epoetin alpha 61 multicenter randomized controlled 61 Follicular Lymphoma 61 Arch Intern Med 61 IIb IV 61 Adjuvant Chemotherapy 61 insulin glulisine 61 Hematologic 61 BEXXAR Therapeutic Regimen 61 T1c 61 Cardiotoxicity 61 chemoradiation therapy 61 elevated ALT 61 Randomized Controlled 61 â ‰ ¥ 61 metastatic malignant 61 heFH 61 metastatic GIST 61 elevated transaminases 61 NCI Cancer 61 cutaneous squamous cell carcinoma 61 MAGE A3 ASCI 61 HCV Genotype 61 See CLINICAL PHARMACOLOGY 61 J Clin Oncol 60 Reduces Mortality 60 underwent surgical resection 60 multivariate Cox 60 cisplatin gemcitabine 60 NMIBC 60 proctitis 60 ara C 60 Peripheral Arterial 60 CLINICAL PHARMACOLOGY 60 Carotid Endarterectomy 60 biochemical relapse 60 Diabetic Neuropathy 60 GOUT 60 GW# [003] 60 Hepatotoxicity 60 HER2 expression 60 Flu Cy 60 MGd 60 Patients Receiving 60 prospective observational cohort 60 colorectal adenoma 60 ZACTIMA 60 RENAL 60 number NCT# ClinicalTrials.gov 60 prospectively enrolled 60 external genital lesions 60 Squamous 60 Histological 60 Primary endpoints 60 non hematologic toxicities 60 Chronic Renal Failure 60 symptomatic VTE 60 Histopathological 60 CALGB 60 B Cell Lymphoma 60 efavirenz EFV 60 Pharmacokinetics PK 60 Estrogen Receptor 60 SEER database 60 Diabetic Foot Ulcer 60 Index CDAI 60 Accelerated Partial Breast Irradiation 60 Subgroup analysis 60 HGPIN 60 Xelox 59 CLL SLL 59 mg BID dose 59 RECIST Response Evaluation Criteria 59 surgically resectable 59 endocrine responsive 59 Shows Statistically Significant 59 Soft Tissue Sarcoma 59 EURIDIS 59 Carotid Revascularization Endarterectomy vs. 59 Pegylated Liposomal Doxorubicin 59 baseline LDH 59 metastatic gastric 59 Retreatment 59 Tumor Response 59 dacarbazine DTIC 59 Gemzar ® 59 pretransplant 59 preoperative PSA 59 Myocardial Infarction TIMI 59 International Prognostic Scoring 59 prognostic variables 59 adenoma recurrence 59 #Gy 59 Basal Cell 59 bronchogenic carcinoma 59 Catheter Associated 59 HDL Selective Delipidation 59 ug dose 59 Angiotensin Converting Enzyme 59 PEG IFN 59 ertapenem 59 Response Evaluation Criteria 59 cranial irradiation 59 Percutaneous Tibial Nerve Stimulation 59 pT2 59 Stenting Trial 59 Clinical Outcome 59 J Clin Endocrinol Metab 59 ARB telmisartan 59 cervical intraepithelial neoplasia 59 Subtypes 59 gastric adenocarcinoma 59 hepatorenal syndrome 59 hypophosphatemia 59 tumor histology 59 F FDG PET 59 thalidomide Thalomid 59 multivariable analysis 59 Invasive Breast Cancer 59 Platinol ® cisplatin 59 Adjuvant chemotherapy 59 univariate analysis 59 Spine Patient Outcomes 59 HIV HCV coinfected 59 Multiple Ascending Dose 59 titrated glipizide 59 unfractionated heparin UFH 59 localized prostate 59 CHAMPION PCI 59 Severe Sepsis 59 neoadjuvant treatment 59 Parathyroid Hormone 59 transrectal ultrasound guided 59 abacavir lamivudine 59 basal cell carcinoma BCC 59 Cholinesterase Inhibitors 58 mg/m2 dose 58 Stenting Trial CREST 58 oral prednisolone 58 cytologic 58 p = #.# [003] 58 receiving Vectibix monotherapy 58 antiretroviral naïve 58 Advanced Melanoma 58 Papillary 58 ER CHOP 58 Motexafin Gadolinium 58 visceral metastases 58 neoplasias 58 BCIRG 58 Solid Tumors 58 hematologic toxicity 58 cutaneous melanoma 58 vincristine doxorubicin 58 Temsirolimus 58 Thrombolysis 58 ECOG PS 58 Renal Cell Carcinoma RCC 58 CIMZIA TM certolizumab pegol 58 bronchial hyperresponsiveness 58 Coronary Artery Bypass Graft 58 TNM classification 58 unresectable tumors 58 #:#-# [024] 58 biopsy Gleason 58 Non Alcoholic Steatohepatitis 58 Fondaparinux 58 Histologic 58 cervical carcinoma 58 moderate hepatic impairment 58 J Clin 58 Prospective Randomized Trial 58 Nebulized 58 Immunohistochemistry 58 postoperative chemotherapy 58 recurrent venous thromboembolism 58 Nanotechnology Characterization Laboratory 58 Shows Promise Against 58 antiepileptics 58 prospective multicentre 58 follicular lymphoma FL 58 ExTRACT TIMI 58 pretreatment serum 58 doxorubicin cyclophosphamide 58 gadobutrol 58 Velcade bortezomib 58 TORISEL TM 58 Clinical Virology 58 Placebo Controlled Trial 58 prospective nonrandomized 58 metastatic pancreatic 58 Teriflunomide 58 pretest probability 58 cancer.gov 58 Accessed #/#/# [001] 58 Bayer HealthCare Onyx Pharmaceuticals 58 Pharmacodynamic 58 advanced hepatocellular carcinoma 58 INCB# [003] 58 Treatment Outcome 58 Pooled Analysis 58 Adenomas 58 dacarbazine chemotherapy 58 Pemetrexed 58 Antiviral Therapy 58 abnormal cytology 58 advanced adenomas 58 Atomoxetine 58 fosbretabulin 58 Gynecologic Oncology Group 58 stage IIIb IV 58 CTEPH 57 deoxy 57 confirmed CCyR 57 mL/min/#.# m 2 57 morphometric vertebral fractures 57 Comorbidities 57 Arch Neurol 57 malignant neoplasm 57 hemorrhagic cystitis 57 transcranial Doppler ultrasound 57 Hurthle cell 57 completely resected 57 Protease Inhibitors 57 metachronous 57 Infusion Reactions Severe 57 Uterine Cancer 57 HBeAg 57 EBUS FNA 57 Improves Outcomes 57 clinico pathological 57 Immunohistochemical staining 57 LAB CGRP 57 Adjunctive 57 Lymphocytic 57 COPERNICUS 57 grade cervical intraepithelial 57 comparator arm 57 Carotid Artery Stenting 57 anticholinergic agents 57 bioavailable testosterone 57 resected pancreatic cancer 57 symptomatic carotid stenosis 57 Relapsing Multiple Sclerosis 57 Folfox 57 prelicensure 57 Mycophenolate Mofetil 57 Psychosomatic Research 57 hematopoietic cancers 57 interstitial brachytherapy 57 ANN INTERN MED 57 nitrofurantoin 57 demonstrated antitumor activity 57 Faslodex 57 Suppl. 57 Hepatocellular Carcinoma HCC 57 Patients Treated With 57 J Natl Cancer Inst 57 observational cohort 57 dual endothelin receptor antagonist 57 meta regression 57 immunohistochemical analysis 57 maternal serum 57 beta carotene supplementation 57 Pegylated Interferon 57 pT3 57 plus 5-FU/LV 57 myelodysplastic myeloproliferative diseases 57 Orthostatic Hypotension 57 ASCUS 57 nondiabetic patients 57 Antitumor 57 prucalopride 57 hormone refractory metastatic prostate 57 paclitaxel cisplatin 57 biliary tract cancer 57 CaPSURE 57 Clostridium difficile Infection 57 endometrial hyperplasia 57 ritonavir boosted lopinavir 57 HCV RESPOND 2 57 Glucosamine Chondroitin Arthritis 57 pain palliation 57 Neoadjuvant 57 undetectable HBV DNA 57 urothelial cancer 57 colorectal liver metastases 57 BR.# 57 advanced adenoma 57 histologically confirmed 57 Ziprasidone 57 Intravitreal 57 Severity Index PASI 57 ILLUSTRATE 57 Leukemias 57 TLUS 57 urothelial carcinoma 57 Doxil ® 57 CA# [006] 57 eribulin mesylate 57 assessing T DM1 57 Dose Ranging Study 57 Randomized Phase 57 Score TOS 57 galiximab 57 5 Fluorouracil 57 Prostate Cancer Prevention 57 fluoropyrimidine 57 achieved CCyR 57 metastatic neuroendocrine tumors 57 undergone radical prostatectomy 57 OSUCCC 57 Controlled Trial 57 β blockers 57 Intervention Trial GAIT 57 Hormone Refractory Prostate Cancer 57 clinicopathological features 57 4mg/kg 57 CC genotype 57 gemcitabine carboplatin 57 univariate 57 Oropharyngeal 57 Severe Asthma 57 CALERIE 57 doxorubicin docetaxel 57 SEER registries 57 randomized multicenter trial 57 subanalysis 57 REMINYL ® 57 antibiotic regimens 57 headache abdominal pain 57 Prostate Cancer Risk 57 fallopian tube carcinoma 57 complement inhibitor eculizumab 57 retrospective cohort 57 NYHA functional class 57 ^ Tc 57 conducted retrospective cohort 57 piperacillin tazobactam 57 Lung Injury 57 Unstable Angina 57 % CI #.#-#.# [007] 57 sorafenib Nexavar 57 specific antigen PSA 57 Kaplan Meier method 57 HLA A2 57 Decitabine 57 Randomized controlled 57 Tigecycline 57 severe oral mucositis 57 KRAS gene mutations 57 Adjuvant Treatment 57 monoclonal antibody conjugated 57 renal cell carcinomas 57 Pancreas Cancer 57 GISSI 57 peritoneal cancer 57 Eli Lilly Gemzar 57 QIDS SR 57 antithymocyte globulin 57 PCPT 57 Kaplan Meier estimates 57 leukocyte count 57 Shows Efficacy 57 hematologic abnormalities 56 Peginterferon 56 Confirms Efficacy 56 Oral Fingolimod 56 dimeglumine 56 % Confidence Interval 56 Screening Trial 56 Myelodysplastic Syndrome MDS 56 Squamous Cell 56 Tumor Microenvironment 56 Double Blind Randomized 56 Myocardial Perfusion Imaging 56 mutated K ras 56 histologically proven 56 Screening Trial DMIST 56 QTcF 56 locoregional recurrence 56 System IPSS 56 clinicopathological 56 Novel Inhibitor 56 Non inferiority 56 DLTs 56 neoplasia CIN 56 Deforolimus 56 NuroPro PD 56 multivariate analyzes 56 homocysteine concentrations 56 HOMA IR 56 pancreatic prostate 56 #mg ATC 56 darunavir r 56 AVOREN 56 Vascugel ® 56 Current Controlled Trials 56 Risk Stratification 56 PegIFN RBV 56 metastatic lymph nodes 56 blinded randomized placebo controlled 56 docetaxel Taxotere ® 56 Echocardiographic 56 LV dysfunction 56 hepatocellular carcinomas 56 prostate cancer CaP 56 Newly Diagnosed Multiple Myeloma 56 hematological parameters 56 liposome injection 56 astrocytomas 56 QTc prolongation 56 Malignant Glioma 56 Captopril 56 Prednisone Against Refractory 56 intradermal injections 56 NATRECOR ® 56 Melphalan 56 Ann Oncol 56 tipranavir ritonavir 56 BARACLUDE ® 56 Proellex TM 56 NNT = 56 tumors GIST 56 standard chemotherapy regimen 56 prospectively defined 56 immunochemical fecal occult 56 refractory chronic lymphocytic 56 EGFR HER2 56 Enzastaurin 56 hormone receptor status 56 targeting miR 56 Naive Patients 56 REYATAZ r arm 56 relapsed ALL 56 Demonstrates Sustained 56 BENICAR HCT 56 mITT population 56 Elitek 56 androgen suppression 56 bronchoalveolar lavage 56 postintervention 56 fluorouracil leucovorin 56 hormone receptor negative 56 conjugated estrogen 56 Renal dysfunction 56 ritonavir boosted 56 prospectively randomized 56 Eur Urol 56 Group RTOG 56 Intervention Effectiveness CATIE 56 PSMA ADC 56 Cancer Epidemiol Biomarkers Prev 56 phase IIIb 56 Perforomist Inhalation Solution 56 metaplasia 56 intraobserver 56 ACTEMRA TM 56 Tesmilifene 56 Myelodysplastic Syndrome 56 doi #.#/S#-# 56 Mammographic 56 denileukin diftitox 56 Stage IIIb 56 Percutaneous Coronary Interventions 56 bleomycin 56 Initiate Phase 56 Bloodstream Infections 56 Sipuleucel T 56 Prospective Randomized 56 FOLFOX4 56 Patient Registry 56 budesonide pMDI 56 intratympanic 56 underwent resection 56 pravastatin Pravachol 56 lymphovascular invasion 56 moderately emetogenic 56 #F FDG PET 56 Edge STudy 56 Colorectal Screening 56 Kidney Disease Outcomes 56 Patency 56 Adjunctive Therapy 56 Schizophrenia Bulletin 56 de novo AML 56 Multicenter Study 56 Multicenter AIDS 56 surgically resected 56 Kaplan Meier 56 TNFerade TM 56 Refractory Hodgkin Lymphoma 56 Patients Undergoing 56 R lenalidomide 56 relapsing multiple sclerosis 56 Tarceva TM 56 Randomized Phase II 56 Symptom severity 56 essential thrombocythemia ET 56 extracolonic findings 56 p = NS 56 guaiac 56 PSA nadir 56 transthyretin amyloidosis 56 RE LY 56 longitudinal observational study 56 treat chronic sinusitis 56 gefitinib Iressa 56 Appropriateness Criteria 56 Lymphoid 56 Trial PCPT 56 Hypotension 56 Evaluation Program CTEP 56 lymphocytosis 56 estramustine 56 biologic DMARD 55 Degarelix 55 CALGB # [002] 55 SLN biopsy 55 nucleoside naive patients 55 CTAP# Capsules 55 coinfected patients 55 MSLT 55 CT Angiography 55 HBeAg negative patients 55 radiotherapy RT 55 IPAH 55 colorectal carcinoma 55 GSK# [001] 55 gene polymorphism 55 carotid artery stenting CAS 55 Prostate Disease 55 erlotinib Tarceva ® 55 PCWP 55 BPS IC 55 5 fluorouracil leucovorin 55 Commences Phase 55 Genes Predict 55 Stroke Scale 55 Interferon alfa 55 ALA PDT 55 odds ratios ORs 55 Immunotherapeutic 55 Ultrasensitive 55 NCT# ClinicalTrials.gov 55 Raloxifene STAR 55 Biochemical Pharmacology 55 resectable 55 Cilostazol 55 TNM staging 55 recurrent glioma 55 ^ sup #m 55 methicillin susceptible Staphylococcus aureus 55 Main Outcome Measure 55 Peginterferon Alfa 2a 55 prospectively stratified 55 postoperative complication 55 irinotecan cisplatin 55 FDG-PET/CT 55 stage IIIA 55 somatostatin analog 55 Squamous Cell Carcinoma 55 SSRI citalopram 55 Colorectal 55 Brief Psychiatric 55 recurrent epithelial ovarian 55 Genome Sequencing Centers 55 polycythemia vera essential thrombocythemia 55 Outcome Measures 55 resectable pancreatic cancer 55 RECORD1 55 RTOG 55 Stage IIB 55 Pre RELAX AHF 55 Critical Limb Ischemia CLI 55 renal artery stenting 55 gastrointestinal toxicities 55 % CI #.#-#.# [003] 55 Global Impression CGI 55 Abstract P# [002] 55 pegylated interferon alfa 2b 55 COSTAR II 55 Mg Usa 55 Prostatic 55 selective phosphodiesterase 55 fluticasone salmeterol 55 CCyR 55 Arch Dermatol 55 Trabectedin 55 atorvastatin #mg 55 GAMMAGARD 55 Glioma 55 SUVmax 55 Heterozygous Familial Hypercholesterolemia 55 Leucovorin 55 Transthyretin 55 Moxifloxacin 55 prostate cancer PCa 55 duplex ultrasonography 55 K ras mutations 55 #:#-# [007] 55 Contrast Agent 55 randomized controlled trials RCTs 55 J Pediatr 55 clinicopathologic 55 #:#-#,# CrossRef Medline [002] 55 Phase III ThermoDox 55 hematologic parameters 55 candesartan cilexetil 55 metastatic colorectal 55 advanced medullary thyroid 55 zoledronic acid Reclast 55 Capecitabine 55 locoregional 55 genotypic resistance 55 differential gene expression 55 treatment naive genotype 55 sleeve lobectomy 55 Angiographic 55 Immunomodulatory 55 certolizumab 55 paclitaxel carboplatin 55 DEB# 55 Secondary endpoints included 55 Intervention Effectiveness 55 pyridostigmine 55 colorectal carcinomas 55 nitroprusside 55 Plaquenil 55 Azacitidine 55 postmenopausal osteoporotic women 55 urinary N telopeptide 55 Tectin TM 55 tarenflurbil 55 esophageal varices 55 recurrent malignant glioma 55 bivariate analyzes 55 debulking surgery 55 dosing cohort 55 diabetes mellitus DM 55 ERalpha 55 epithelial ovarian 55 ULORIC 55 ASSERT 55 Prognostic Value 55 multicentric 55 clinically localized prostate 55 8mg/kg 55 Metastatic Melanoma 55 cisplatin resistant 55 GH deficiency 55 postoperative mortality 55 Acute Decompensated Heart Failure 55 suppl. 55 corticosteroid dose 55 aldosterone antagonists 55 Decompensated Heart Failure 55 mcg QD 55 moderate renal impairment 55 Iron Deficiency Anemia 55 treat benign prostatic 55 serum GGT 55 vismodegib 55 AST ALT 55 atherosclerotic renal artery stenosis 55 thyroglobulin 55 REYATAZ ® 55 extracapsular extension 55 enzyme immunoassay EIA 55 Systemic Lupus Erythematosus SLE 55 CLARITY TIMI 55 transvaginal sonography 55 AA Amyloidosis 55 BMI z 55 #mg/day [001] 55 nadroparin 55 chemoradiotherapy 55 ALT flares 55 retrospectively analyzed 55 ug kg 55 BZA CE 55 endometrial carcinoma 55 longitudinal cohort study 55 Trandolapril 55 Crohn Disease Activity 55 radiolabeled TM# 55 TRUS 55 Hodgkin lymphoma HL 55 intact parathyroid hormone 55 Polyp Prevention Trial 55 Prospective Multicenter 55 Interferon Alfa 55 cisplatin vinorelbine 55 PANSS Positive 55 Sociodemographic 55 prostate carcinoma 55 mCi kg 55 Clinical Antipsychotic Trials 55 Y BOCS 55 huN# DM1 55 liver metastasis 55 medullary thyroid carcinoma 55 nonsevere 55 DAS# remission 55 Mg Uk 55 nodal metastasis 55 p# biomarker 55 5alpha reductase 55 Epirubicin 55 chronic idiopathic thrombocytopenic purpura 55 Combination Treatment 55 KRAS mutations occur 55 Successfully Completes Phase 55 -#.# ± [002] 55 ACR# ACR# 55 Diabetes Interventions 55 CIN3 55 Acute Ischemic Stroke 55 HbA 1c levels 55 LHRH receptor positive 55 Cancer Institute www.cancer.gov 55 cTnI 55 HCV SPRINT 55 azacytidine 55 #:#-#,# Medline 55 Chemoradiation 55 pancreatic adenocarcinoma 55 BRIM3 55 invasive lobular carcinoma 55 TASKi3 55 microgram kg 55 multidetector computed tomography 55 epithelial tumors 55 Navelbine ® 55 Cytogenetic 55 carotid stenosis 55 pegylated liposomal doxorubicin 55 adriamycin 55 Skin sterol 55 grade squamous intraepithelial 55 Community Acquired Pneumonia 55 Fluorouracil 55 aripiprazole Abilify 55 Chronic HCV 55 MDRD 55 Hemoglobin A1c 55 #:#-#,# [002] 55 mycophenolate mofetil 55 multiple logistic regression 55 Cholesterol Levels SPARCL 55 alpha1 antitrypsin deficiency 55 Dialysis Outcomes 54 idiopathic membranous nephropathy 54 chemoprevention trials 54 papillary thyroid carcinoma 54 Molecular Epidemiology 54 Clinical Psychopharmacology 54 NIH CPSI 54 melanoma ovarian 54 Valopicitabine 54 Castration Resistant Prostate Cancer 54 rosuvastatin #mg 54 graft occlusion 54 HepDirect prodrug 54 neoadjuvant 54 gastroduodenal 54 DAS# CRP 54 Study Evaluating 54 esophageal carcinoma 54 Randomized Evaluation 54 hyperlipidemia hypertension 54 epirubicin 54 ACE Inhibitors 54 Chronic lymphocytic leukemia 54 conventional angiography 54 Postmenopausal hormone therapy 54 dosimetric 54 Bosentan 54 Adjuvant Therapy 54 CIMZIA ™ 54 HER2 Positive Breast Cancer 54 Viral Load 54 NICE SUGAR 54 adjuvant radiotherapy 54 #.#mg/dL 54 Psoriasis Area 54 Engerix B 54 periprocedural 54 ADCS CGIC 54 Pfizer Camptosar 54 nonmelanoma skin cancers 54 prospectively evaluated 54 Gastric Cancer 54 Chemoprevention 54 sunitinib Sutent 54 Hypertrophy 54 interrater reliability 54 PANVAC VF 54 Brain Metastases 54 recurrent NSCLC 54 Metastatic Prostate Cancer 54 patients undergoing CABG 54 Multivariate logistic regression 54 thymoma 54 administered intramuscularly 54 CYT# potent vascular disrupting 54 DMSA 54 rFVIIa 54 TheraCIM h R3 54 LRTI 54 PhG alpha 1 54 Suicidality 54 CAPRIE 54 neo adjuvant 54 thyrotropin levels 54 finasteride Proscar 54 radioimmunotherapy RIT 54 urine albumin 54 percutaneous vertebroplasty 54 PREZISTA r 54 Investigator Initiated 54 ® lenalidomide 54 Meets Primary Endpoint 54 NCCTG N# 54 adalimumab Humira 54 NS# [004] 54 Fracture Risk 54 fluvastatin 54 Bronchopulmonary Dysplasia 54 interferon ribavirin 54 preoperative chemotherapy 54 pediatric malignancies 54 gallium nitrate 54 Prophylactic Treatment 54 Lung Cancer Trial 54 Initiated Phase 54 erythropoietic 54 receptor tyrosine kinase inhibitor 54 fluvastatin Lescol 54 lopinavir r arm 54 total thyroidectomy 54 generalized edema 54 histopathologic examination 54 HPV-#/# 54 Investigational Drug 54 Malignancies 54 venous thromboembolic disease 54 topical calcineurin inhibitors 54 ACUITY trial 54 Visual Analogue Scale VAS 54 Hepatocellular Carcinoma 54 Patient Outcomes 54 Lymph node 54 distant metastasis 54 Diagnostic Criteria 54 neratinib 54 Cystectomy 54 chronic thromboembolic pulmonary 54 Fingolimod 54 protease inhibitor PI 54 multivariable Cox 54 interobserver reliability 54 noscapine 54 spirometric 54 symptomatic pulmonary embolism 54 quadrivalent HPV vaccine 54 Impaired glucose tolerance 54 secondary efficacy endpoint 54 osteosarcomas 54 Phase Ib II 54 venlafaxine Effexor 54 IIIA NSCLC 54 anaplastic astrocytomas 54 Kahalalide F 54 evaluating tivozanib 54 atazanavir ritonavir 54 multigene expression test 54 R# #mg BID 54 antiangiogenic agent 54 relapsing remitting MS RRMS 54 ALT elevation 54 pharmacodynamic parameters 54 Chronic Myelogenous Leukemia CML 54 μg liter 54 tipranavir r 54 CellSearch ™ 54 Contrast Agents 54 T1a 54 Complicated Skin 54 CYP#D# inhibitor 54 ATACAND 54 Prognostic significance 54 Neuroendocrine Tumor 54 Raloxifene Evaluation MORE 54 ALN HPN 54 Glycopyrrolate 54 SSc 54 Tanespimycin 54 invasive lobular 54 Lancet Oncology journal 54 Multicentre 54 reactogenicity 54 Intra arterial 54 rizatriptan 54 mycosis fungoides 54 Malignant Melanoma 54 diagnosing coronary artery 54 noncancer 54 Breast Density 54 chromium supplementation 54 everolimus eluting stents 54 lumbar spine BMD 54 Adefovir 54 YERVOY 54 squamous 54 stage IIIB 54 ACOSOG Z# 54 mild hepatic impairment 54 HYVET 54 Secondary Hyperparathyroidism 54 IIIb 54 TO AVOID PREGNANCY WHILE 54 artery embolization 54 danazol 54 subcutaneous immunoglobulin 54 Long Term Efficacy 54 Achieves Primary Endpoint 54 interferon gamma 1b 54 baseline FEV 54 Improves Survival 54 EUS FNA 54 Cyclophosphamide 54 Aflibercept 54 conditional logistic regression 54 sorafenib tablets 54 NMES 54 HSCT 54 Aggressive Reduction 54 mycophenolate 54 confidence intervals CIs 54 AIR2 Trial 54 Triapine R 54 carotid endarterectomy CEA 54 Nesiritide 54 pregabalin Lyrica 54 Systemic Sclerosis 54 Metabolic Bone Disease 54 VeriStrat 54 Demonstrated Significant 54 annexin 54 metaanalysis 54 multivariate logistic regression 54 trastuzumab DM1 T DM1 54 GSTP1 54 metastatic lung cancer 54 Kaplan Meier analysis 54 prospective multicenter study 54 definite stent thrombosis 54 Meta analyzes 54 underwent CABG 54 Ann Emerg Med 54 Main Outcome Measures 54 receiving ISENTRESS 54 pegylated interferon alfa 54 Neuroepidemiology 54 BRCA1 BRCA2 54 digital subtraction angiography